Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2012New Report
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL).
View full press release